Pfizer wants to give the vaccine to people as young as 18 to protect them against high-risk adults

Pfizer said the shot, approved for adults age 60 and older, had similar effects in adults over age 18. Pfizer: The shot was approved for those over 60 and had similar effect on adults over 18. The shot is available for adults over 60 years old and under 60.

Pfizer plans to file for an expanded approval of Abrysvo, currently approved for adults ages 60 and above and expectant mothers. Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use. Abryvo is currently approved.

Pfizer to seek approval for RSV vaccine for people as young as 18 who are at increased risk of the disease. Pfizer will submit the information to the US Food and Drug Administration for potential expansion of the vaccine’s availability to people ages 18 to 59.